Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of inactivated varicella-zoster vaccine V212 in adults with autoimmune disease
NL-OMON37443Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2012
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zoster vaccine live in herpes zoster (HZ) (3 arms), sponsored by Merck & Co. Primary endpoints: Primary immunogenicity endpoint and Primary safety endpoint. Started Jul 2012; status: active, not recruiting.
02
Drugs
zoster vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NL-OMON37443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37443.